When the US FDA relies on real-world evidence, it is most commonly for rare disease applications with breakthrough designations. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
